BEDFORD, Mass., October 3, 2017 – Homology Medicines, Inc., a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients, announced today that Company management will be presenting during the 2017 Cell & Gene Meeting on the Mesa, organized by the Alliance for Regenerative Medicine and the Sanford Stem Cell Clinical Center at UC San Diego.
Homology executives will participate in a panel titled, “The Gene Editing Challenge: Validating Platform Technologies,” on Thursday, October 5 at 9:15 a.m. PT and will deliver a corporate presentation at 11:15 a.m. PT at the Estancia La Jolla Hotel & Spa in California.
The Cell & Gene Meeting on the Mesa is the largest partnering meeting organized specifically for the cell and gene therapy sector. The event’s Partnering Forum on October 4-5 features more than 70 dedicated company presentations in addition to 90 panelists and featured speakers.
About Homology Medicines, Inc.
Homology Medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The combination of a new multidimensional technology platform and a management team that has successfully developed and commercialized rare disease therapies uniquely positions the Company to move beyond the current limitations of gene therapy and gene editing approaches to improve patient care. Homology Medicines has built foundational intellectual property on gene editing and gene therapy using vectors derived from naturally occurring human adeno-associated viruses (AAVs). The Company’s technology is precise, on-target and highly efficient for in vivo editing of genetic mutations. The unique team and technology create a significant opportunity for Homology Medicines to rapidly advance a diverse pipeline of new medicines that address and potentially cure the underlying cause of genetic diseases. For more information, please visit www.homologymedicines.com.